We should be done in such a way that patients with stage IV non-small cell lung cancer who would benefit from surgery are not overlooked

The standard treatment for stage IV non-small cell lung cancer (NSCLC) is systemic chemotherapy; however, survival rates are poor (1). Furthermore, most patients with NSCLC have stage IV disease at the time of diagnosis (2). As oncologists, we should consider using the best treatment strategies for stage IV NSCLC patients.